Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Rallybio Corporation

< Previous 1 2 Next >
Rallybio Reports Second Quarter 2023 Financial Results and Provides Business Updates
From Rallybio Corporation
Via Business Wire
Tickers RLYB
Rallybio to Present at the 2023 Wedbush PacGrow Healthcare Conference
From Rallybio Corporation
Via Business Wire
Tickers RLYB
Rallybio Announces Acceptance of Abstract for RLYB116 at the 29th International Complement Workshop (ICW)
From Rallybio Corporation
Via Business Wire
Tickers RLYB
Rallybio Announces Succession Plan; Appoints Stephen Uden, M.D., as Chief Executive Officer, Effective August 1, 2023
From Rallybio Corporation
Via Business Wire
Tickers RLYB
Rallybio Announces Proof-of-Concept Results and Development Updates for RLYB212, a Novel Monoclonal anti-HPA-1a Antibody to Prevent Fetal and Neonatal Alloimmune Thrombocytopenia
From Rallybio Corporation
Via Business Wire
Tickers RLYB
Rallybio to Present Data from the RLYB212 Phase 1b Proof-of-Concept Study at the 31st Congress of the International Society on Thrombosis and Haemostasis
From Rallybio Corporation
Via Business Wire
Tickers RLYB
Rallybio to Present at the Jefferies Healthcare Conference
From Rallybio Corporation
Via Business Wire
Tickers RLYB
Rallybio Reports First Quarter 2023 Financial Results
From Rallybio Corporation
Via Business Wire
Tickers RLYB
Rallybio to Present at the JMP Securities 2023 Life Sciences Conference
From Rallybio Corporation
Via Business Wire
Tickers RLYB
Rallybio Announces Clinical Proof-of-Concept Results for RLYB211, an Anti-HPA-1a Polyclonal Antibody for the Prevention of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT), Published in the Journal of Thrombosis and Haemostasis
From Rallybio Corporation
Via Business Wire
Tickers RLYB
Rallybio Announces Acceptance of Abstract for RLYB212 at the 31st Congress of the International Society on Thrombosis and Haemostasis (ISTH)
From Rallybio Corporation
Via Business Wire
Tickers RLYB
Rallybio Reports Fourth Quarter and Full Year 2022 Financial Results
From Rallybio Corporation
Via Business Wire
Tickers RLYB
Rallybio Announces Proof-of-Concept Achieved for RLYB212, a Novel Monoclonal anti-HPA-1a Antibody to Prevent Fetal and Neonatal Alloimmune Thrombocytopenia
From Rallybio Corporation
Via Business Wire
Tickers RLYB
Rallybio to Present at Upcoming Investor Conferences in March
From Rallybio Corporation
Via Business Wire
Tickers RLYB
EyePoint and Rallybio Announce Research Collaboration to Evaluate Rallybio’s Inhibitor of Complement Component 5 (C5) and EyePoint’s Proprietary Durasert® Technology for Sustained Intraocular Delivery in Geographic Atrophy
From Rallybio Corporation
Via Business Wire
Tickers RLYB
Rallybio Announces Appointment of Jonathan I. Lieber as Chief Financial Officer
From Rallybio Corporation
Via Business Wire
Tickers RLYB
Rallybio Highlights Portfolio Advances and Outlines Expected Milestones in 2023
From Rallybio Corporation
Via Business Wire
Tickers RLYB
Rallybio Announces Publication of Data Highlighting the Ability of HPA-1a-Specific Antibodies to Prevent Alloimmunization in an Authentic Mouse Model of FNAIT
From Rallybio Corporation
Via Business Wire
Tickers RLYB
AbCellera and Rallybio Announce Strategic Alliance to Discover, Develop, and Commercialize Novel Antibody-Based Therapeutics for Rare Diseases
From Rallybio Corporation
Via Business Wire
Tickers ABCL RLYB
Rallybio to Present at the JMP Securities Hematology and Oncology Summit
From Rallybio Corporation
Via Business Wire
Tickers RLYB
Rallybio to Present at Upcoming Investor Conferences in November
From Rallybio Corporation
Via Business Wire
Tickers RLYB
Rallybio Announces Proposed Public Offering
From Rallybio Corporation
Via Business Wire
Tickers RLYB
Rallybio Reports Third Quarter 2022 Financial Results
From Rallybio Corporation
Via Business Wire
Tickers RLYB
Rallybio Announces Positive Phase 1 Single Ascending Dose Results for RLYB116, an Innovative Subcutaneously Injected Inhibitor of Complement Component 5
From Rallybio Corporation
Via Business Wire
Tickers RLYB
Rallybio Announces Positive Preliminary Results for RLYB212, an anti-HPA-1a Monoclonal Antibody for the Prevention of Fetal and Neonatal Alloimmune Thrombocytopenia
From Rallybio Corporation
Via Business Wire
Tickers RLYB
Rallybio to Present at the 2022 Wells Fargo Healthcare Conference
From Rallybio Corporation
Via Business Wire
Tickers RLYB
Rallybio Reports Second Quarter 2022 Financial Results
From Rallybio Corporation
Via Business Wire
Tickers RLYB
Rallybio Appoints Wendy K. Chung, M.D., Ph.D., to Its Board of Directors
From Rallybio Corporation
Via Business Wire
Tickers RLYB
Rallybio Announces Retirement of Jeffrey Fryer, CPA, Chief Financial Officer
From Rallybio Corporation
Via Business Wire
Tickers RLYB
Rallybio to Present at Upcoming Investor Conferences in June
From Rallybio Corporation
Via Business Wire
Tickers RLYB
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.